CYRX
NASDAQ
US
CryoPort, Inc. - Common Stock
$8.77
▲ +$0.26
(+3.06%)
Vol 239K
12
Quality Score
ok
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$480.7M
P/E
7.1
ROE
14.8%
Margin
35.5%
D/E
36.50
Beta
1.66
52W
$5–$11
Wall Street Consensus
16 analysts · Apr 20266
Strong Buy
8
Buy
2
Hold
0
Sell
0
Strong Sell
87.5%
Buy Rating
Price Chart
Similar Stocks
BLFS
BioLife Solutions Inc
$1.2B
FTRE
Fortrea Holdings Inc
$1.6B
PSNL
Personalis Inc
$706.9M
CTKB
Cytek Biosciences Inc
$645.7M
MLAB
Mesa Laboratories Inc
$433.5M
MRVI
Maravai LifeSciences Holdings Inc
$831.0M
NAUT
Nautilus Biotechnology Inc
$246.3M
PACB
Pacific Biosciences of California Inc
$564.6M
LAB
Standard BioTools Inc
$492.2M
OABI
OmniAb Inc
$266.3M
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.21 | $-0.27 | $-0.06 |
| Sep 2025 | $-0.22 | $-0.18 | +$0.04 |
| Jun 2025 | $-0.24 | $2.05 | +$2.29 |
| Mar 2025 | $-0.32 | $-0.28 | +$0.04 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $59.5M | $41.0M | $45.5M | $44.2M | $45.5M |
| Net Income | — | -$18.7M | -$12.0M | $105.2M | -$6.9M | -$11.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 17.4% | 17.4% | 17.4% | 17.4% | 14.8% | 14.8% |
| P/E (TTM) | 4.97 | 5.88 | 6.30 | 6.14 | 6.78 | 7.11 |
| Net Margin | 231.4% | 37.2% | 37.2% | 37.2% | 35.5% | 35.5% |
| Gross Margin | 47.0% | 45.7% | 45.7% | 45.7% | 46.6% | 46.6% |
| D/E Ratio | 36.32 | 36.32 | 36.32 | 36.32 | 36.50 | 36.50 |
| Current Ratio | 16.24 | 16.24 | 16.24 | 16.24 | 15.77 | 15.77 |
Key Ratios
ROA (TTM)
9.2%
P/S (TTM)
2.53
P/B
1.0
EPS (TTM)
$1.34
CF/Share
$-0.59
Rev Growth 3Y
+0.9%
52W High
$11.44
52W Low
$4.58
$4.58
52-Week Range
$11.44
Financial Health
Free Cash Flow
-$4.0M
Net Debt
-$19.8M
Cash
$250.5M
Total Debt
$230.7M
As of Dec 31, 2025
How does CYRX compare to Life Sciences Tools & Services peers?
Peer group: Small-cap Life Sciences Tools & Services ($300M+) · 25 companies
CYRX valuation vs Life Sciences Tools & Services peers
P/E ratio
7.1
▼
78%
below
peers
(32.5)
vs Peers
vs Industry
Undervalued
P/S ratio
2.5
▼
34%
below
peers
(3.8)
vs Peers
vs Industry
Undervalued
P/B ratio
1.0
▼
74%
below
peers
(3.7)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.5%)
vs Peers
vs Industry
Low yield
CYRX profitability vs Life Sciences Tools & Services peers
ROE
14.8%
▲
552%
above
peers
(-3.3%)
vs Peers
vs Industry
Top tier
Net margin
35.5%
▲
478%
above
peers
(-9.4%)
vs Peers
vs Industry
Top tier
Gross margin
46.6%
▼
3%
below
peers
(48.0%)
vs Peers
vs Industry
Weak
ROA
9.2%
▲
452%
above
peers
(-2.6%)
vs Peers
vs Industry
Top tier
CYRX financial health vs Life Sciences Tools & Services peers
D/E ratio
36.5
▼
0%
below
peers
(36.5)
vs Peers
vs Industry
In line
Current ratio
15.8
▲
367%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.7
▲
17%
above
peers
(1.4)
vs Peers
vs Industry
More volatile
CYRX fundamentals radar
CYRX
Peer median
Industry
CYRX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CYRX vs peers: key metrics
Latest News
No related news yet